CORT - NASDAQ
Corcept Therapeutics Incorporated
$72.65
+1.8%Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotCorcept Therapeutics Incorporated Management Team
Mr. Joseph Douglas Lyon
Chief Accounting & Technology Officer
Mr. Gary Charles Robb J.D.
Chief Business Officer & Secretary
Compensation
$1,242,845
Dr. William Guyer Pharm.D.
Chief Development Officer
Compensation
$1,189,408
Mr. Atabak Mokari
Chief Financial Officer & Treasurer
Compensation
$980,383
Ms. Amy Flood
Chief Human Resources & Communications Officer
Dr. Hazel Hunt Ph.D.
Chief Scientific Officer
Compensation
$895,156
Dr. Joseph K. Belanoff M.D.
Co-Founder, President, Chief Executive Officer & Director
Compensation
$2,879,533
Ms. Monica Tellado
President of Emerging Markets
Mr. Sean Maduck
President of Endocrinology
Compensation
$1,120,268
Mr. Roberto W. Vieira
President of Oncology
Corcept Therapeutics Incorporated Insider Positioning
During the last 12 months, insiders have purchased $813K and sold $32.74M worth of CORT shares, resulting in $31.93M of net selling activity.
3 Months
24.2K
812.84K
211.4K
11.86M
-11.0M
-$11.05M
3-6 Months
0
0.00
48.2K
1.82M
-1.8M
-$1.82M
6-9 Months
0
0.00
159.8K
12.77M
-12.8M
-$12.77M
9-12 Months
0
0.00
88.1K
6.29M
-6.3M
-$6.29M
Top Buyers
Baker G Leonard Jr
Director
$813K
Top Sellers
Guyer William
Officer: Chief Development Officer
$11.25M
Belanoff Joseph K
Director, Officer: Chief Executive Officer
$9.25M
Maduck Sean
Officer: See Remarks
$9.18M
Lyon Joseph Douglas
Officer: See Remarks
$1.85M
Swisher Daniel N Jr
Director
$823K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $31.93M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
CORT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | April 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | April 10, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 14, 2023 | April 14, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | April 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | April 22, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | April 27, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 24, 2019 | June 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 24, 2018 | May 29, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | May 24, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.